EMEleonora Martinis

Eleonora Martinis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eleonora Martinis has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Alessandra Colamatteo

    Treg Cell Lab, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli ‘Federico II’, Napoli, Italy

    1 shared publication
  • Alessandro Uzzau

    Dipartimento di Medicina, Università degli Studi di Udine, Udine, Italy

    1 shared publication
  • Andrea Cossarizza

    Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia School of Medicine, Modena, Italy

    1 shared publication
  • Barbara Frossi

    Laboratorio di Immunologia, Dipartimento di Medicina, Università degli Studi di Udine, Udine, Italy

    1 shared publication
  • Carlo Pucillo

    Laboratorio di Immunologia, Dipartimento di Medicina, Università degli Studi di Udine, Udine, Italy

    1 shared publication
  • Carolina Ricci

    Laboratorio di Immunologia, Dipartimento di Medicina, Università degli Studi di Udine, Udine, Italy

    1 shared publication

Latest Publications

  • Open Access

    Immunophenotypic skewing of B cells toward IgD⁻CD27⁻IgG⁺ subtype and metabolic attenuation in colorectal cancer

    by Eleonora Martinis, Silvia Tonon, Viviana Valeri, Alessandra Colamatteo, Carolina Ricci, Caterina Trevisan, Eleonora Capezzali, Matteo Pivetta, Serena Battista, Marta Mozzon, et al.

    Colorectal cancer (CRC) is the third most prevalent cancer and understanding its tumor microenvironment (TME) is crucial for the development of innovative therapies. Despite the presence of B cells in CRC infiltrate, their clinical significance is poorly understood. In this study, we observed an enrichment of double-negative (DN) B cells, a subset lacking surface IgD and CD27, in CRC biopsies. Typically underrepresented in physiological conditions, DN B cells expand in certain chronic infections, autoimmune diseases, and cancers. Within this subpopulation, low CD21 expression—a phenotypic hallmark of exhaustion—was observed. Consistently, DN B cells displayed low metabolic activity. Accordingly, total B cells infiltrating CRC tissues showed a diminished capacity to differentiate into antibody-secreting cells (ASCs) upon stimulation. In the murine setting, CRC organoids decreased the frequency of ASCs in co-cultured B cells and induced metabolic dysfunction, marked by altered glucose and fatty acid uptake and dysregulated expression of key metabolic proteins. Moreover, B cells displayed reduced glycolysis and mitochondrial respiration, despite increased mitochondrial dependence. This study provides evidence for DN B cell accumulation within CRC infiltrate and metabolic reprogramming of B cells, suggesting that targeting B cell metabolism may represent a promising strategy to potentiate anti-tumor immune responses.


  • Open Access

    Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer

    by Eleonora Martinis, Carolina Ricci, Caterina Trevisan, Gaia Tomadini, Silvia Tonon

    Colorectal cancer represents 10% of all new cancer cases each year and accounts for almost 10% of all cancer deaths. According to the WHO, by 2040 there will be a 60% increase in colorectal cancer cases. These data highlight the need to explore new therapeutic strategies. Classical interventions include surgical resection, chemotherapy and radiotherapy, which are invasive strategies that have many side effects on the patients and greatly affect their quality of life. A great advance in the treatment of this cancer type, as well as of all the others, could be the development of a vaccination strategy preventing the onset, the progression or the relapse of the pathology. In this review, we summarize the main vaccination strategies that are being studied for the treatment of colorectal cancer (CRC) and finally explore the possibility of using B-cells for the development of a new type of vaccine.